SCHEMBL5649502

SCHEMBL5649502

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc(Cl)c(C)cc3[nH]2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 7/20 0.55
RHEB Q15382 1/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HTT P42858 2/20 0.48
MAPK1 P28482 2/20 0.48
TSHR P16473 1/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HDAC4 P56524 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44
HPSE Q9Y251 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649514 0.96 PRSS12 (0.55) PRSS12RHEBHDAC6HTTMAPK1
SCHEMBL5649071 0.93 PRSS12 (0.62) PRSS12RHEBHDAC6HTTMAPK1
SCHEMBL5651811 0.90 PRSS12 (0.54) PRSS12RHEBHDAC6HTTMAPK1
SCHEMBL5651653 0.89 HTT (0.49) PRSS12HDAC6HTTMAPK1TSHR
SCHEMBL5651824 0.88 PRSS12 (0.54) PRSS12RHEBHDAC6HTTMAPK1
SCHEMBL5653265 0.87 TP53 (0.47) PRSS12HDAC6HTTMAPK1TSHR
SCHEMBL5651963 0.87 HTT (0.47) PRSS12HDAC6HTTMAPK1TSHR
SCHEMBL5651793 0.86 PRSS12 (0.56) PRSS12RHEBPTGDR2
SCHEMBL5649315 0.86 HDAC6 (0.54) PRSS12HDAC6TSHRHDAC4HDAC2
SCHEMBL5651662 0.85 HTT (0.49) PRSS12HDAC6HTTMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRSS12 979/4885RHEB 946/4885HDAC6 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.